Fourth Quarter 2025 Earnings Conference Call February 19, 2026 Forward Looking Statements The information contained in this presentation includes statements based on management's current expectations, estimates and projections that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include statements regarding the company's anticipated financial and operating performance, relate to future events and expectations and involve kno ...

Core Viewpoint - CV Sciences held its Third Quarter 2025 Earnings Conference Call, where key executives presented the financial results and future outlook of the company [1][2]. Financial Results - The company issued a press release detailing its financial results for the third quarter of 2025, which participants were encouraged to review for a summary of the results [5]. Management Commentary - The call featured prepared remarks from the Chief Executive Officer, Joseph Dowling, and Chief Financial Officer, Joerg Grasser, who provided insights into the company's performance and strategic direction [2]. Forward-Looking Statements - Management's remarks included forward-looking statements that are subject to risks and uncertainties, indicating that actual results may differ from expectations [3]. Non-GAAP Financial Measures - The company discussed non-GAAP financial measures, which exclude certain expenses from GAAP results, and provided a reconciliation of these measures in the press release [4].

Lucid Diagnostics - EsoGuard revenue reached $1.2 million in Q3 2025, with a test volume of 2,841[9] - A MolDX Contractor Advisory Committee (CAC) meeting unanimously endorsed Medicare coverage for EsoGuard[9] - The company strengthened its balance sheet by netting approximately $27 million in proceeds from an underwritten public offering of common stock[9] Veris Health - Veris Health launched the commercial phase of its strategic partnership with OSU[11] - The company relaunched implantable physiological monitor development, targeting a 2026 FDA 510(k) submission[11] Financial Performance - The company's cash reserves were $3.103 million in 3Q25, a decrease of $901 thousand from $4.004 million in 2Q25[16] - Equity method investments in Lucid were valued at $31.615 million in 3Q25, down $4.383 million from $35.998 million in 2Q25[16] - Revenue plus management fee income was $3.155 million in 3Q25, a decrease of $991 thousand compared to $4.146 million in 3Q24[18] - The company reported a net loss of $6.011 million in 3Q25, a significant change from a net income of $60.711 million in 3Q24[18] - Non-GAAP adjusted loss was $(446) thousand in 3Q25, compared to $(5,439) thousand in 3Q24[18] - Shares outstanding increased to 23.1 million in 3Q25 from 20.1 million in 2Q25[16]

Core Insights - Dream Residential REIT reported Q3 2025 financial results, highlighting a net operating income increase and a strategic acquisition agreement with Morgan Properties [1][3][43] Financial Performance - Comparative properties net operating income (NOI) was $6.4 million in Q3 2025, a 4.5% increase from Q3 2024, driven by a 3.0% rise in investment properties revenue [3][6] - Net rental income for Q3 2025 was $7.8 million, consistent with the prior year [3][7] - Diluted funds from operations (FFO) per Unit remained at $0.18 for Q3 2025, unchanged from Q3 2024 [3][5] - Total equity decreased to $172.8 million as of September 30, 2025, down from $240.5 million at the end of 2024 [6][14] Portfolio and Occupancy - Portfolio occupancy was 93.7% as of September 30, 2025, down from 95.2% at the end of Q2 2025 [3][8] - Average monthly rent increased to $1,195 per unit from $1,186 at the end of Q2 2025 [3][9] - Tenant retention ratio improved to 59.9% in Q3 2025 compared to 57.4% in Q2 2025 [10][8] Strategic Developments - The strategic review concluded with an agreement for Morgan Properties to acquire Dream Residential REIT for $10.80 per unit in an all-cash transaction [3][43] - The acquisition was approved by unitholders on October 16, 2025, and received court approval on October 21, 2025 [3][44] Value-Add Initiatives - Renovations were completed on 13 units in the Greater Cincinnati region during Q3 2025, with an average new lease trade-out of $232 per unit higher than expiring leases [11][3] Financing and Capital Structure - As of September 30, 2025, net total debt-to-net total assets was 38.2%, with total debt at $146.5 million [13][40] - Available liquidity was approximately $61.6 million, consisting of $7.6 million in cash and $54 million in an undrawn credit facility [13][36]

Core Viewpoint - The QVC Group is conducting its Third Quarter 2025 Earnings Conference Call, indicating a focus on financial performance and future outlook [1]. Financial Performance - The call will discuss non-GAAP financial measures such as adjusted OIBDA, adjusted OIBDA margin, free cash flow, and constant currency, highlighting the importance of these metrics in evaluating the company's performance [3]. Leadership - Key speakers on the earnings call include QVC Group President and CEO David Rawlinson and the CFO, emphasizing the leadership's role in communicating financial results and strategic direction [4].

Group 1 - The company reported strong financial performance in the first half of 2025, highlighting excellent execution against its strategic framework [4] - The presentation included participation from key executives, including the CEO, CFO, and Chief Product and Technology Officer, indicating a collaborative approach to the results presentation [1] - The results announcement and supplementary data are available for download on the company's investor relations website, providing transparency and access to detailed financial information [3] Group 2 - The CEO emphasized the importance of the first half of 2025, suggesting that the period was significant for the company's growth and strategic initiatives [4] - The CFO is expected to provide detailed financial insights, indicating a structured approach to communicating financial results [4] - The company may make forward-looking statements, which are subject to various factors that could affect actual results, underscoring the dynamic nature of the hospitality industry [2]

Financial Performance - PAVmed's Q1 2025 revenue and management fee income was $3158 thousand, a decrease of $352 thousand compared to $3510 thousand in Q1 2024[23] - The company's operating expenses decreased significantly from $15046 thousand in Q1 2024 to $5454 thousand in Q1 2025, a reduction of $9592 thousand[23] - Net income for Q1 2025 was $18623 thousand, a substantial improvement of $37135 thousand compared to a loss of $18512 thousand in Q1 2024[23] - PAVmed reported an EBITDA of $19007 thousand in Q1 2025, compared to a negative EBITDA of $14813 thousand in Q1 2024, an increase of $33820 thousand[23] - Non-GAAP adjusted loss improved by $7705 thousand, from a loss of $8615 thousand in Q1 2024 to a loss of $910 thousand in Q1 2025[23] - Non-GAAP adjusted loss per share improved from $(099) in Q1 2024 to $(007) in Q1 2025, an increase of $092[23] Balance Sheet - PAVmed's cash position increased by $1515 thousand, from $1185 thousand in 4Q24 to $2700 thousand in 1Q25[22] - Equity method investments in Lucid increased by $21004 thousand, from $25637 thousand in 4Q24 to $46641 thousand in 1Q25[22] - Senior secured convertible notes decreased by $22500 thousand, from $29100 thousand in 4Q24 to $6600 thousand in 1Q25[22] - Preferred shares outstanding were 24480 thousand in 1Q25[22] - Shares outstanding increased from 112 million to 168 million, an increase of 56 million shares[22] Business Updates - Lucid Diagnostics' EsoGuard revenue for Q1 2025 was $08 million, with a test volume of 3034[17] - PAVmed strengthened its balance sheet by netting approximately $161 million in proceeds from an underwritten public offering of common stock[17]

Group 1 - The Fossil Group held its First Quarter 2025 Earnings Call, with key participants including CEO Franco Fogliato and CFO Randy Greben [1][2] - The call included forward-looking statements, with a reminder that actual results may differ materially from those discussed [3] - The company referred to constant currency results and non-GAAP financial measures, with reconciliations available in the earnings release [4]

Core Insights - XPO reported first quarter 2025 financial results with diluted earnings per share of $0.58, up from $0.56 in Q1 2024, while adjusted diluted earnings per share decreased to $0.73 from $0.81 year-over-year [1][7][8] - Total revenue for Q1 2025 was $1.95 billion, a decline of 3.2% compared to $2.02 billion in Q1 2024, primarily due to lower fuel surcharge revenue in the North American LTL segment [6][10] - The company achieved adjusted EBITDA of $278 million, down from $288 million in the same quarter last year, reflecting a 3.5% decrease [8][49] Financial Performance - North American Less-Than-Truckload (LTL) segment revenue was $1.17 billion, a 4.0% decrease from $1.22 billion in Q1 2024, with operating income of $158 million, down from $165 million [10][11] - European Transportation segment revenue decreased by 1.9% to $782 million, with operating income improving to $1 million from a loss of $4 million [11][42] - Corporate segment reported an operating loss of $9 million, significantly improved from a loss of $23 million in the previous year [11][46] Operational Efficiency - The adjusted operating ratio for North American LTL improved to 85.9%, reflecting a cumulative improvement of 370 basis points over two years [5][10] - The company reported a year-over-year reduction in purchased transportation expenses by 53%, contributing to enhanced cost efficiency [5][10] - XPO's first quarter yield growth, excluding fuel, accelerated to 6.9%, with revenue per shipment improving for the ninth consecutive quarter [5][10] Cash Flow and Capital Expenditures - XPO generated $142 million in cash flow from operating activities in Q1 2025, ending the quarter with $212 million in cash and cash equivalents after $191 million in net capital expenditures [9][28]